Augmented Anticancer Efficacy of Doxorubicin-Loaded Polymeric Nanoparticles after Oral Administration in a Breast Cancer Induced Animal Model
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The present investigation reports an extensive evaluation of in vitro and in vivo anticancer efficacy of orally administered doxorubicin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Dox-NPs) in a breast cancer induced animal model. Spherically shaped Dox-NPs were prepared with an entrapment efficiency and particle size of 55.40 ± 2.30% and 160.20 ± 0.99 nm, respectively, and freeze-dried with 5% trehalose using stepwise freeze-drying. Cytotoxicity, as investigated on C127I cell line, revealed insignificant differences between the IC(50) of free Dox and Dox-NPs treated cells in the first 24 h, while higher cytotoxicity was demonstrated by Dox-NPs, following 72 h of incubation. Confocal laser scanning microscopy (CLSM) imaging corroborated that nanoparticles were efficiently localized into the nuclear region of C127I cells. The cellular uptake profile of Dox-NPs revealed both time and concentration dependent increases in the Caco-2 cell uptake as compared to the free Dox solution. Further, Dox-NPs significantly suppressed the growth of breast tumor in female Sprague-Dawley (SD) rats upon oral administration. Finally, orally administered Dox-NPs showed a marked reduction in cardiotoxicity when compared with intravenously injected free Dox as also evident by the increased level of malondialdehyde (MDA), lactate dehydrogenase (LDH), and creatine phosphokinase (CK-MB) and reduced levels of glutathione (GSH) and superoxide dismutase (SOD). The reduced cardiotoxicity of orally administered Dox-NPs was also confirmed by the major histopathological changes in the heart tissue after the treatments of intravenously injected free Dox and orally delivered Dox-NPs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“when the efficacy of WGA-coated allergen-loaded microspheres was evaluated in birch pollen-sensitized mice, oral treatment did not induce an allergen-specific isotype switch towards IgG2a or the production of the Th1 cytokine IFN-γ in comparison to gavages of plain microspheres [74].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [74]
In the citing paper
“in a 7,12-dimethylbenz[a]anthracene-induced breast cancer rat model, oral administration of doxorubicin loaded PLGA NPs revealed a higher antitumor efficacy as a result of enhanced bioavailability, tumor permeation and retention effect [74].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [74]
In the citing paper
“incorporation of doxorubicin into PLGA nanospheres significantly reduced the doxorubicin-induced cardiotoxicity [74].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [74]
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Freeze-drying of nanoparticles: Formulation, process and storage considerations
ABDELWAHED, W., DEGOBERT, G., STAINMESSE, S., & FESSI, H. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.017 · Cited by 1,611
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
Yin Win, K., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.07.050 · Cited by 1,452
Govender, T. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00116-3 · Cited by 1,008
Artursson, P. (1990) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600790604 · Cited by 844
Synthesis and characterization of PLGA nanoparticles
Astete, C. E., & Sabliov, C. M. (2006) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856206775997322 · Cited by 776
Chitosan nanoparticles as delivery systems for doxorubicin
Janes, K. A., Fresneau, M. P., Marazuela, A., Fabra, A., & Alonso, M. J. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00294-2 · Cited by 721
Doxorubicin cardiotoxicity: analysis of prevailing hypotheses
Olson, R. D., & Mushlin, P. S. (1990) · The FASEB Journal · doi:10.1096/fasebj.4.13.2210154 · Cited by 690
Hussain, N. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00152-1 · Cited by 680
Mitra, S., Gaur, U., Ghosh, P. C., & Maitra, A. N. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00342-x · Cited by 647
Caco-2 Cell Monolayers as a Model for Drug Transport Across the Intestinal Mucosa
Hilgers, A. R., Conradi, R. A., & Burton, P. S. (1990) · Pharmaceutical Research · doi:10.1023/a:1015937605100 · Cited by 587
The Oral Absorption of Micro- and Nanoparticulates: Neither Exceptional Nor Unusual
Florence, A. T. (1997) · Pharmaceutical Research · doi:10.1023/a:1012029517394 · Cited by 499
Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs
Dong, Y., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.03.021 · Cited by 395
Antioxidant nutrients and adriamycin toxicity
Quiles, J. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00383-9 · Cited by 362
Stereochemistry of Intercalation: Interaction of Daunomycin with DNA
PIGRAM, W. J., FULLER, W., & HAMILTON, L. D. (1972) · Nature New Biology · doi:10.1038/newbio235017a0 · Cited by 358
Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.
Olson, R. D., Mushlin, P. S., Brenner, D. E., Fleischer, S., Cusack, B. J., Chang, B. K., & Boucek, R. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.10.3585 · Cited by 357
Wong, H. L., Bendayan, R., Rauth, A. M., Xue, H. Y., Babakhanian, K., & Wu, X. Y. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101154 · Cited by 344
P-Glycoproteins and Multidrug Resistance
Bellamy, W. T. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.001113 · Cited by 319
Upadhyay, K. K., Bhatt, A. N., Mishra, A. K., Dwarakanath, B. S., Jain, S., Schatz, C., Le Meins, J.-F., Farooque, A., Chandraiah, G., Jain, A. K., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.12.043 · Cited by 316
Self-citationDong, X., Mattingly, C. A., Tseng, M. T., Cho, M. J., Liu, Y., Adams, V. R., & Mumper, R. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2747 · Cited by 290
Betancourt, T., Brown, B., & Brannon-Peppas, L. (2007) · Nanomedicine · doi:10.2217/17435889.2.2.219 · Cited by 249
Kalaria, D. R., Sharma, G., Beniwal, V., & Ravi Kumar, M. N. V. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9763-4 · Cited by 246
Exploiting M cells for drug and vaccine delivery
Clark, M. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00149-1 · Cited by 246
Sangeetha, P. (1990) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(90)90139-a · Cited by 235
Jain, A. K., Swarnakar, N. K., Godugu, C., Singh, R. P., & Jain, S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.037 · Cited by 232
Self-citationDe Beer, E. L., Bottone, A. E., & Voest, E. E. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00765-8 · Cited by 185
Second cancers following non-Hodgkin's lymphoma
Travis, L. B., Curtis, R. E., Boice, J. D., Hankey, B. F., & Fraumeni, J. F. (1991) · Cancer · doi:10.1002/1097-0142(19910401)67:7<2002::aid-cncr2820670729>3.0.co;2-e · Cited by 178
Borst, P., Schinkel, A. H., Smit, J. J. M., Wagenaar, E., Van Deemter, L., Smith, A. J., Eijdems, E. W. H. M., Baas, F., & Zaman, G. J. R. (1993) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(93)90011-2 · Cited by 170
Enhanced Oral Bioavailability of Doxorubicin in a Dendrimer Drug Delivery System
Ke, W., Zhao, Y., Huang, R., Jiang, C., & Pei, Y. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21155 · Cited by 165
Kattan, J. G., Droz, J., Couvreur, P., Marino, J. P., Boutan-Laroze, A., Rougier, P. R., Brault, P., Vranckx, H., Grognet, J., Morge, X., et al. (1992) · Investigational New Drugs · doi:10.1007/bf00877245 · Cited by 153
Bhardwaj, V., Ankola, D. D., Gupta, S., Schneider, M., Lehr, C., & Kumar, M. N. V. R. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9965-4 · Cited by 145
Yadav, A. K., Mishra, P., Mishra, A. K., Mishra, P., Jain, S., & Agrawal, G. P. (2007) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2007.09.004 · Cited by 138
Self-citationBallinger, J. R., Bannerman, J., BOXEN, I., Firby, P., Hartman, N., & Moore, M. J. (1996) · PubMed · Cited by 131
Dextran–doxorubicin/chitosan nanoparticles for solid tumor therapy
Bisht, S., & Maitra, A. (2009) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.43 · Cited by 126
Bardelmeijer, H. A., Beijnen, J. H., Brouwer, K. R., Rosing, H., Nooijen, W. J., Schellens, J. H. M., & van Tellingen, O. (2000) · PubMed · Cited by 121
Perez, A. T., Domenech, G. H., Frankel, C., & Vogel, C. L. (2002) · Cancer Investigation · doi:10.1081/cnv-120014883 · Cited by 114
Varma, M., Khandavilli, S., Ashokraj, Y., Jain, A., Dhanikula, A., Sood, A., Thomas, N., Pillai, O., Sharma, P., Gandhi, R., et al. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335423 · Cited by 107
Self-citationWeight gain with breast cancer adjuvant treatment
Levine, E. G., Raczynski, J. M., & Carpenter, J. T. (1991) · Cancer · doi:10.1002/1097-0142(19910401)67:7<1928::aid-cncr2820670718>3.0.co;2-9 · Cited by 100
Yadav, A. K., Mishra, P., Jain, S., Mishra, P., Mishra, A. K., & Agrawal, G. P. (2008) · Journal of Drug Targeting · doi:10.1080/10611860802095494 · Cited by 99
Self-citationReddy, L. H., & Murthy, R. S. R. (2004) · Biomedical Papers · doi:10.5507/bp.2004.029 · Cited by 93
The tumor blood vessel as an ideal target for macromolecular anticancer agents
Maeda, H. (1992) · Journal of Controlled Release · doi:10.1016/0168-3659(92)90086-7 · Cited by 81
Yeung, T. K., Hopewell, J. W., Simmonds, R. H., Seymour, L. W., Duncan, R., Bellini, O., Grandi, M., Spreafico, F., Strohalm, J., & Ulbrich, K. (1991) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00687318 · Cited by 77
Turakhia, S., Venkatakrishnan, C. D., Dunsmore, K., Wong, H., Kuppusamy, P., Zweier, J. L., & Ilangovan, G. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00328.2007 · Cited by 69
Jain, S., Mittal, A., Jain, A., Mahajan, R. R., & Singh, D. K. (2010) · Current Nanoscience · doi:10.2174/157341310791658937 · Cited by 64
Self-citationKogure, K., Hama, S., Manabe, S., Tokumura, A., & Fukuzawa, K. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00344-0 · Cited by 49
Coenzyme Q content depends upon oxidative stress and dietary fat unsaturation
Mataix, J., Mañas, M., Quiles, J. L., Battino, M. A., Cassinello, M., López‐Frías, M., & Huertas, J. R. (1997) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(97)00019-8 · Cited by 41
Rehm, S. (1990) · Europe PMC (PubMed Central) · Cited by 27
Tang, X., Xie, P., Ding, Y., Chu, L., Hou, J.-P., Yang, J., Song, X. Y., & Xie, Y. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.12.076 · Cited by 23
Effect of glutamine on the initiation and promotion phases of DMBA‐induced mammary tumor development
Kaufmann, Y., Kornbluth, J., Feng, Z., Fahr, M. J., Schaefer, R., & Klimberg, V. (2003) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607103027006411 · Cited by 18
Research works printed but not linked: 3
- Bardelmeijer H. A., 2000, Clin. Cancer Res., 6, 4416
- Rehm S., 1990, Am. J. Pathol., 136, 575
- Ballinger J. R., 1996, J. Nucl. Med., 37, 1578
Cited by
Oral delivery of anticancer drugs: Challenges and opportunities
Thanki, K., Gangwal, R. P., Sangamwar, A. T., & Jain, S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.020 · Cited by 499
Self-citationJain, A. K., Thanki, K., & Jain, S. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400311j · Cited by 235
Self-citationHSA Coated Iron Oxide Nanoparticles as Drug Delivery Vehicles for Cancer Therapy
Quan, Q., Xie, J., Gao, H., Yang, M., Zhang, F., Liu, G., Lin, X., Wang, A., Eden, H. S., Lee, S., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200006f · Cited by 223
Jain, S., Rathi, V. V., Jain, A. K., Das, M., & Godugu, C. (2012) · Nanomedicine · doi:10.2217/nnm.12.31 · Cited by 174
Self-citationAgrawal, A. K., Harde, H., Thanki, K., & Jain, S. (2014) · Biomacromolecules · doi:10.1021/bm401580k · Cited by 170
Self-citation
Metadata
- Authors
- Jain, A. K., Swarnakar, N. K., Das, M., Godugu, C., Singh, R. P., Rao, P. R., & Jain, S.
- Affiliations
- National Institute of Pharmaceutical Education and Research (IN)
- Corresponding author
- Jain, Sanyog
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-05-25
- Volume
- 8
- Issue
- 4
- Pages
- 1140-1151
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2332972932
- Cited by
- 89
- References
- 52
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 5 · 2020: 2 · 2019: 3 · 2018: 12 · 2017: 5 · 2016: 7 · 2015: 10 · 2014: 4 · 2013: 15 · 2012: 7
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- doxorubicin, PLGA nanoparticles, oral drug delivery, breast cancer, cardiotoxicity, nanoparticle cytotoxicity, cellular uptake, freeze-drying, Caco-2 cells, tumor growth inhibition, antioxidant enzymes, cardiac histopathology
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Antineoplastic Agents, Breast Neoplasms, Creatine Kinase, Doxorubicin, Female, Glutathione, Humans, L-Lactate Dehydrogenase, Malondialdehyde, Polyglycolic Acid, Superoxide Dismutase, Rats, Sprague-Dawley, Microscopy, Atomic Force, Caco-2 Cells, Lactic Acid, Cell Line, Tumor, Mice, Kaplan-Meier Estimate, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.